SecBot SecBot
SECBOTREPLAY Home › Report › CGEN

CGEN · Compugen reported Q1 2026 results with revenue of $2.2M (vs $2.3M in Q1…

COMPUGEN LTD · 6-K filed May 18, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 4/10

6-K filed May 18, 2026 at 07:00 ET

Compugen reported Q1 2026 results with revenue of $2.2M (vs $2.3M in Q1 2025) and net loss of $7.7M ($0.08/share) vs $7.2M ($0.08/share) in the prior year. Cash and equivalents stood at $134.9M with runway into 2029. Clinical milestones remain on schedule: COM701 MAIA-ovarian interim analysis by Q1 2027, AstraZeneca advancing rilvegostomig across 11 Phase 3 trials, and Gilead-partnered GS-0321 Phase 1 progressing. The filing is a routine quarterly update with no-surprise update with no material financial deviation from the prior period.

  • Q1 2026 revenue $2.2M vs $2.3M in Q1 2025, essentially flat with a slight decline
  • Net loss $7.7M ($0.08/shr) vs $7.2M ($0.08/shr) in Q1 2025, slightly wider loss, EPS unchanged
  • Cash, equivalents, short-term deposits, and marketable securities of $134.9M as of March 31, 2026
  • Cash runway expected to fund operations into 2029 with no debt

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access